Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial
American Journal of Hematology · 2025-09 · 100 (9) · 1533-1542
DOI: 10.1002/ajh.27746 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, online erschienen am 19.06.2025. Verfasst von Yimei Feng und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Blood Platelets, Thrombopoietin, Pyrazoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Chongqing Technology Innovation and Application Development Project, National Natural Science Foundation of China, Youth Project of National Health Commission.
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is pivotal for hematological malignancies but faces challenges in delayed platelet engraftment, poor graft function (PGF), and bleeding risks. Hetrombopag, a thrombopoietin receptor agonist, was evaluated to enhance platelet recovery posttransplant. Patients undergoing allo‐HSCT were randomized on Day 3 Post‐Infusion into low‐dose (2.5 mg/day), high‐dose (5 mg/day) hetrombopag groups, or a control group receiving thrombopoietin (300 U/kg/day). Endpoints included platelet/neutrophil engraftment time, PGF incidence, transfusion needs, and safety. Among 212 analyzed patients, platelet engraftment was faster in hetrombopag groups (median 13 days) versus controls (15 days; p = 0.0022), with no dose‐dependent difference ( p = 0.0593). Neutrophil engraftment was also accelerated (13 vs. 15 days; p = 0.0001). PGF incidence was lower in hetrombopag groups (5.04%) versus controls (13.7%; p = 0.027). The experimental group required fewer platelet transfusions ( p = 0.002), had reduced gastrointestinal bleeding, and lower costs. Secondary platelet recovery failure showed no intergroup differences. Hetrombopag safely accelerates platelet and neutrophil engraftment, reduces PGF risk, and decreases transfusion dependency post‐allo‐HSCT. Low‐dose hetrombopag demonstrated efficacy equivalent to high‐dose, offering a cost‐effective strategy to improve transplant outcomes. Trial Registration: ChiCTR2200057764.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Affiliated Hospital of Army Medical University, Chongqing, China.
- Department of Hematology, Guizhou Provincial People's Hospital, Guiyang, China.
- Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- Department of Hematology, The General Hospital of Western Theater Command, Chengdu, China.
- Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
- Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Yimei Feng, Xiaoning Wang, Han Yao, Xi Zhang
Förderung
- Chongqing Technology Innovation and Application Development Project
- National Natural Science Foundation of China
- Youth Project of National Health Commission
- Clinical Research Special Project at the Second Affiliated Hospital of Army Medical University
Zitieren
APA
Feng, Y., Wang, L., Ren, M., Wang, D., Lang, T., Deng, J., Lou, S., Yi, H., Ma, L., Xing, H., He, P., Wang, X., Wang, S., Wang, J., Yao, H., Chen, T., Liu, J., Zhao, L., Liu, Y., …, & Zhang, X. (2025). Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial. American Journal of Hematology, 100(9), 1533-1542. https://doi.org/10.1002/ajh.27746
Vancouver
Feng Y, Wang L, Ren M, Wang D, Lang T, Deng J, et al. Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial. American Journal of Hematology. 2025;100(9):1533-1542. doi:10.1002/ajh.27746
BibTeX
@article{Feng2025,
author = {Feng, Yimei and Wang, Linhui and Ren, Mingqiang and Wang, Dan and Lang, Tao and Deng, Jianchuan and Lou, Shifeng and Yi, Hai and Ma, Liangliang and Xing, Hongyun and He, Pengcheng and Wang, Xiaoning and Wang, Sanbin and Wang, Jishi and Yao, Han and Chen, Ting and Liu, Jia and Zhao, Lu and Liu, Yuqing and Wang, Xiaoqi and Li, Li and Tang, Shuhan and Zhu, Lidan and Liu, Jia and Gao, Shichun and Liu, Huanfeng and Wang, Lu and Kong, Peiyan and Gao, Lei and Zhang, Xi},
title = {Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {9},
pages = {1533--1542},
doi = {10.1002/ajh.27746}
}
EUVIMED